Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gum Tech International was a specialty pharmaceutical company that focused on the development and commercialization of unique drug delivery systems. The company is best known for developing Zicam, a popular line of homeopathic cold remedies that utilized zinc gluconate. Their primary technological innovation involved a patented gel delivery system designed to keep active ingredients in contact with the nasal mucosa for extended periods. Additionally, the company explored the use of medicated chewing gums as a delivery vehicle for various over-the-counter and prescription medications. In 2000, Gum Tech was acquired by its primary distributor, The Quigley Corporation, which later rebranded as ProPhase Labs. The Zicam brand remains a significant player in the cough and cold market today.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gum Tech International.